SciBase lands another customer in the US
The announced partnership is with Seraly Dermatology in Pittsburgh, Pennsylvania. The customer will integrate several Nevisense systems into their skin cancer detection workflow. According to Seraly Dermatology’s website, they have a single location with a staff of 5, so the client seems to be small. Still, each customer win is a sign that the market response to Nevisense remains good and that the product continues to be well positioned.
SciBase mentioned in the press release that they are expanding to a new market. We assume Seraly Dermatology was their first customer in Pennsylvania, which could indicate that insurance coverage for Nevisense diagnostics in the state is on a positive trend. Our revenue growth estimates for Scibase assume steady customer wins, so this deal will not cause any changes to our revenue forecasts.
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille
Scibase Holding
SciBase Holding is a global medical technology group specialized in diagnostics and prevention in dermatology. The company develops, produces and commercializes Nevisense, a patient-centered platform that combines AI (artificial intelligence) with EIS technology to enable early detection and intervention of skin cancer and other skin diseases. Nevisense is based on over 20 years of research at Karolinska Institutet, the headquarters are in Stockholm.
Lue lisää yhtiösivulla